Peter Sondermann

Peter is co-founder and CEO of Tacalyx. He gained his track record within the field of therapeutic antibodies and other proteins during his work as CSO and CEO of SuppreMol which was acquired in March 2015 by Baxter Bioscience/Baxalta and as “Head Process Biochemistry” at Glycart biotechnology AG, Schlieren/Switzerland which was acquired by Roche in 2005.

Peter has studied chemistry which he completed with PhD. He is inventor of more than 10 patents/patent applications and has authored +30 peer-reviewed scientific articles.